Ahmed El-Balat1, Iryna Schmeil2, Thomas Karn2, Uwe Holtrich2, Loreta Mavrova-Risteska2, Achim Rody3, Aly Youssef4, Lars C Hanker3. 1. Department of Obstetrics and Gynecology, Goethe-University, Frankfurt, Germany ahmed.el-balat@kgu.de. 2. Department of Obstetrics and Gynecology, Goethe-University, Frankfurt, Germany. 3. Department of Obstetrics and Gynecology, University Hospital Schleswig-Holstein, Lübeck, Germany. 4. Department of Obstetrics and Gynecology, Sant'Orsola-Malpighi University Hospital, University of Bologna, Bologna, Italy.
Abstract
BACKGROUND/AIM: Totally implanted venous access devices (TIVAD) are increasingly used in the treatment of cancer patients. The aim of this study was to assess the incidence of early and late complications resulting from subcutaneous TIVADs in patients with breast cancer. MATERIALS AND METHODS: Between 2004 and 2009, we reviewed patients with breast cancer who had a TIVAD placed. Early and late complications, as well as risk factors for TIVAD-associated thrombosis were retrospectively assessed. RESULTS: A total of 281 patients were included. Complications occurred in 26% of patients, the majority of which were late complications (21.4%.) The development of TIVAD associated thrombosis was the most frequent late complication (16.4%). In the univariate analysis followed by a multivariate model, risk factors for TIVAD associated thrombosis were not identified. Only within the subgroup of metastatic breast cancer patients an increased risk of TIVAD-associated thrombosis of left compared to right venous access was detected (p=0.015). CONCLUSION: TIVAD implantation done in a gynecological outpatient setting is feasible and safe. Copyright
BACKGROUND/AIM: Totally implanted venous access devices (TIVAD) are increasingly used in the treatment of cancerpatients. The aim of this study was to assess the incidence of early and late complications resulting from subcutaneous TIVADs in patients with breast cancer. MATERIALS AND METHODS: Between 2004 and 2009, we reviewed patients with breast cancer who had a TIVAD placed. Early and late complications, as well as risk factors for TIVAD-associated thrombosis were retrospectively assessed. RESULTS: A total of 281 patients were included. Complications occurred in 26% of patients, the majority of which were late complications (21.4%.) The development of TIVAD associated thrombosis was the most frequent late complication (16.4%). In the univariate analysis followed by a multivariate model, risk factors for TIVAD associated thrombosis were not identified. Only within the subgroup of metastatic breast cancerpatients an increased risk of TIVAD-associated thrombosis of left compared to right venous access was detected (p=0.015). CONCLUSION:TIVAD implantation done in a gynecological outpatient setting is feasible and safe. Copyright
Authors: Panagiotis Samaras; Stefan Dold; Julia Braun; Peter Kestenholz; Stefan Breitenstein; Alexander Imhof; Christoph Renner; Frank Stenner-Liewen; Bernhard C Pestalozzi Journal: Oncology Date: 2008-08-21 Impact factor: 2.935